Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThere is no clinical evidence that NAD (nicotinamide adenine dinucleotide) supplements interact harmfully with tirzepatide (Mounjaro), and they are not listed as a contraindication in the Mounjaro SmPC. That said, NAD supplements are not regulated as medicines in the UK, the research on combining them with GLP-1 or dual-agonist treatments is essentially absent, and a prescriber should know about everything you take alongside a prescription medicine. Mounjaro is a prescription-only medicine requiring clinical assessment before it can be supplied — any additional supplements are worth discussing openly at that stage.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is probably the most common assumption our prescribers encounter with supplement questions, and it deserves a direct correction. 'Natural' does not mean inert. NAD itself is a coenzyme found in every cell of the body, and the supplements people take (usually in the form of precursors such as nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN)) are designed to raise intracellular NAD levels. That's a biological effect, not a passive one.
What's actually true is narrower: there is no published clinical trial, no pharmacokinetic study and no regulatory guidance specifically addressing NAD precursors alongside tirzepatide. The absence of a known interaction and the absence of harm are not the same thing. For a medicine as recently approved as Mounjaro (still carrying the Black Triangle (▼) symbol indicating it is under additional post-market surveillance by the MHRA) the honest position is that the combination simply hasn't been studied. You can read the full ingredient-level detail in the Mounjaro Summary of Product Characteristics on the eMC, which lists known interactions and contraindications.
The practical upshot: there is no red flag in the official data, but there is also no green light from a clinical trial. Your prescriber needs the full picture of what you take. That includes NAD supplements.
Mounjaro works partly by slowing gastric emptying, food and anything else in the stomach moves through to the small intestine more slowly than usual. This is one of the reasons it reduces appetite and post-meal blood-sugar spikes. It also means that orally taken capsules and tablets, including food supplements, may be absorbed at a different rate or to a different extent than they would be without tirzepatide on board.
For most supplements this probably matters very little in practice. But NMN and NR capsules are typically taken first thing in the morning, sometimes alongside other tablets, think of the routine: supplements lined up next to the kettle before breakfast. If gastric emptying is slowed, the timing and extent of absorption could shift. Nobody has measured this for NAD precursors specifically, so quantifying the effect isn't possible. What's reasonable is to mention it to your prescriber, who can advise whether timing adjustments make sense for you.
For a broader look at how Mounjaro interacts with other concurrent treatments, the guidance on taking Mounjaro alongside HRT covers a related example of how absorption considerations play out in practice. If you're also curious about other concurrent supplements, the page on CBD and Mounjaro addresses a similar evidence gap in the same honest terms.
GLP-1 and dual-agonist medicines like tirzepatide are prescribed after a clinical review that covers your full health picture, including what you already take. This isn't box-ticking. A prescriber who knows you're taking NAD supplements can note it in your record, flag anything that subsequently emerges in post-market surveillance, and give you personalised timing advice if they think it's warranted.
The NHS guidance on weight-management injections (available at NHS England's dedicated page) consistently emphasises that the safety of treatment depends on a complete clinical picture, not just the medicine in isolation. That principle applies whether you're combining tirzepatide with a prescribed medicine or with an over-the-counter supplement.
People sometimes hesitate to mention supplements because they assume a prescriber won't take them seriously, or will simply say stop. In practice, most prescribers are pragmatic: if there's no signal of harm and you want to continue, that's a conversation, not a ban. The important thing is that the conversation happens. For wider context on how our prescribers approach combination questions, the tirzepatide overview explains the full assessment process, and the page on taking other GLP-1 medicines with Mounjaro covers the higher-stakes end of interaction queries. Questions about how IBS or other gut conditions interact with treatment are covered at Mounjaro and IBS.
If you're considering starting Mounjaro and want a prescriber to review your full supplement and medicine list from the outset, the place to begin is a free consultation. Those who want to understand the commercial side of the treatment can also find a breakdown of how Mounjaro profits are generated and distributed across the supply chain. At nume's weight-loss treatment page you can check your eligibility and have your answers read the same day by a GPhC-registered Independent Prescriber, not processed by an automated system.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.